These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 997532)
1. [Field trial with a new type of influenza subunit vaccine (author's transl)]. Kunz C; Hofmann H Wien Klin Wochenschr; 1976 Aug; 88(15):504-8. PubMed ID: 997532 [TBL] [Abstract][Full Text] [Related]
2. [Immunisation against influenza with a new subunit vaccine tested on children at risk (author's transl)]. Luthardt T; Lutz O; Kindt H Dtsch Med Wochenschr; 1979 Jan; 104(2):56-60. PubMed ID: 759142 [TBL] [Abstract][Full Text] [Related]
3. Clinical trials with a new influenza subunit vaccine in adults and children. Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz AJ Dev Biol Stand; 1977 Jun 1-3; 39():297-302. PubMed ID: 342311 [TBL] [Abstract][Full Text] [Related]
4. [A new influenza subunit vaccine: reactogenicity and antigenicity in comparison to split and whole virus vaccines (author's transl)]. Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz A; SchmidtG Infection; 1976; 4(2):73-9. PubMed ID: 947849 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Hehme N; Engelmann H; Kuenzel W; Neumeier E; Saenger R Virus Res; 2004 Jul; 103(1-2):163-71. PubMed ID: 15163505 [TBL] [Abstract][Full Text] [Related]
6. [Antibody response to hemagglutinin and neuraminidase induced by an influenza subunit vaccine (author's transl)]. Kuwert E; Werner J; Franke G; Paulus W Zentralbl Bakteriol Orig A; 1979 Jun; 244(1):1-16. PubMed ID: 92113 [TBL] [Abstract][Full Text] [Related]
7. [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza I. Hemagglutinationinhibiting antibodies (author's transl)]. Kuwert EK; Werner J; Scheiermann N; Pledt T Zentralbl Bakteriol Orig A; 1979 Jul; 244(2-3):155-74. PubMed ID: 506543 [TBL] [Abstract][Full Text] [Related]
8. A study of acute respiratory disease in the community of Port Chalmers. III. Efficacy of influenza virus subunit vaccines in 1973, 1974 and 1975. Jennings LC; MacDiarmid RD; Miles JA N Z Med J; 1980 Sep; 92(668):230-3. PubMed ID: 6935541 [TBL] [Abstract][Full Text] [Related]
9. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine]. Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the antigenicity and tolerance of an influenza aluminium oxide adsorbate vaccine with an aqueous vaccine. Pressler K; Peukert M; Schenk D; Borgoño M Pharmatherapeutica; 1982; 3(3):195-200. PubMed ID: 7134227 [TBL] [Abstract][Full Text] [Related]
11. Live attenuated influenza virus vaccine trial in children. Hall CB; Douglas G; Fralonardo SA Pediatrics; 1975 Dec; 56(6):991-8. PubMed ID: 1196767 [TBL] [Abstract][Full Text] [Related]
12. [Reactivity and immunologic activity of polyvalent split influenza vaccine in children]. Závadová H; Domorázková E; Skovránková J; Vodicková M; Ragac P; Vonka V Cesk Pediatr; 1990 Jun; 45(6):344-6. PubMed ID: 2289253 [TBL] [Abstract][Full Text] [Related]
13. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330 [TBL] [Abstract][Full Text] [Related]
15. [Safety of an influenza-split-vaccine in children]. Schmitt-Grohé S; Banzhoff A; Klaassen B; Zielen S Klin Padiatr; 2001; 213(6):338-42. PubMed ID: 11713714 [TBL] [Abstract][Full Text] [Related]
16. [Influenza vaccination in dialysis patients]. Haldimann B; Descoeudres C Schweiz Med Wochenschr; 1978 Jan; 108(2):52-5. PubMed ID: 622534 [TBL] [Abstract][Full Text] [Related]
17. E-rosette forming cells and humoral antibody titres in humans after vaccination with three different inactivated influenza virus vaccines A/USSR/92/77 (H1N1). Schmidt S; Süss J; Oehring H; Schmidt J Acta Virol; 1982 Dec; 26(6):466-73. PubMed ID: 6132540 [TBL] [Abstract][Full Text] [Related]
18. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Camilloni B; Neri M; Lepri E; Iorio AM Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623 [TBL] [Abstract][Full Text] [Related]
19. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]